All News | RheumNow

All News

Cyclosporin and IVIG Effective in Kawasaki's Disease

Save

d Jack Cush, MD

Mar 19, 2019

A Lancet study has shown that adding cyclosporin to intravenous immunoglobulin (IVIG) Kawasaki disease patients, who were predicted to be resistant to IVIG, was both safe and effective in averting severe coronary artery outcomes.

Read Article

gout.bunion.jpg

Ironwood Retreats from the US Gout Market

Save

d Jack Cush, MD

Mar 18, 2019

Ironwood Pharmaceuticals discontinued the marketing and sales of both lesinurad (Zurampic) the combination drug of lesinurad and allopurinol (Duzallo) in the United States effective February 1, 2019.

Read Article

cancer.cross_.jpg

No Rise in Cancer Risk with Actemra

Save

d RheumNow

Mar 18, 2019

In patients with rheumatoid arthritis (RA), there was no increased risk for malignancy development seen with newly initiated tocilizumab (Actemra) treatment, an analysis of three U.S. insurance claim databases found.

Read Article

CRA Position Statement on Medical Cannabis Use

Save

d Jack Cush, MD

Mar 15, 2019

Courtesy of the Canadian Rheumatology Association (CRA) website, here are consensus guidelines on medical cannabis use.

Rheumatology patients experience prevalent pain that is only modestly controlled with current treatment strategies.

Read Article

RN.podcast.resized.jpg

RheumNow Podcast – You Owe Me a DEXA (3.15.19)

Save

d Jack Cush, MD

Mar 15, 2019

Dr. Jack Cush reviews this week's news and highlights from RheumNow.com.

Read Article

Study of 151,305 pts from Clinical Practice Research Datalink, shows that THR/TKR patients exposed to statins for 1-5 years had ~25% reduced risk of arthroplasty revision (HR 0.74 (0.62, 0.88)). https://t.co/AQhKHuAwkD

Links:

https://buff.ly/2ThWoJx

Dr. John Cush RheumNow ( View Tweet)

Mar 20, 2019

Pain signaling via NMDA receptors in the brain can be treated with drugs that block NMDA receptors (ketamine, methadone, memantine, amantadine, dextromethorphan). Metanalysis of memantine (15 studies) shows little benefit. https://t.co/72yfYzDXhV

Links:

https://buff.ly/2W9KuTK

Dr. John Cush RheumNow ( View Tweet)

Mar 20, 2019

Brain fog (Fibro Fog) is common with sleep disorders and fibromyalgia. Manifests as memory problems, poor mental focus, forgetfulness - all correctable with sleep medicine evaluation and sleep assistance. https://t.co/e6CXXkYV39

Links:

https://buff.ly/2D3UE3J

Dr. John Cush RheumNow ( View Tweet)

Mar 19, 2019

Study of 21,016 SLE patients from Korean Health Claims databases shows SLE patients have a higher risk of cancer than controls (OR 1.44; 95% CI 1.33–1.56) with highre rates of cervical, thyroid, ovarian, oral cancer, lymphoma, leukemia, & multiple myeloma https://t.co/NKR9i4ccfU

Links:

https://buff.ly/2W8DxT4

Dr. John Cush RheumNow ( View Tweet)

Mar 19, 2019

Time to register for this weeks RheumNow Live. Free online streaming video - 16 hrs of Innovative lectures and Q&A Panels from friday afternoon 3/22, till noon Sunday 3/24. Register for FREE at https://t.co/wIgS5rq4UE

Links:

https://buff.ly/2VRUAbQ

Dr. John Cush RheumNow ( View Tweet)

Mar 19, 2019

QD Clinic - When To Stop MTX- Should/Can a Patient ever stop MTX? | RheumNow https://t.co/z0Dhwdbr3Q

Links:

https://buff.ly/2Wczsx7

Dr. John Cush RheumNow ( View Tweet)

Mar 18, 2019

European Commission Approves MabThera (rituximab) for use in Pemphigus, US FDA approved it in 6/18; RTX is now approved in 4 autoimmune disorders in the US & Europe (RA, GPA, MPA, Pemphigus) - Not approved for use in children https://t.co/dJJfPdXuWQ(rituxim/364143/index.html

Links:

https://buff.ly/2Td0bYj

Dr. John Cush RheumNow ( View Tweet)

Mar 18, 2019

Nice comprehensive full read review of the Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline from the JBMR. https://t.co/Eh9xfPJ2B0

Links:

https://buff.ly/2Y4Rovp

Dr. John Cush RheumNow ( View Tweet)

Mar 18, 2019

Vedolizumab superior to adalimumab in clinical remission (31 vs 22%) and mucosal healing(40 vs 28%) at week 52 when given to383 patients with moderate to severely active ulcerative colitis. Data presented at European Crohn’s and Colitis Congress. https://t.co/dXrEkzhnKh

Links:

https://buff.ly/2W5L2dh

Dr. John Cush RheumNow ( View Tweet)

Mar 18, 2019

Daily noninvasive ultrasound (US) stimulation of the spleen significantly reduces disease severity in a murine model of inflammatory arthritis. Results mediated via T & B cell effects as T/B deficient mice did not improve with splenic US. https://t.co/dSlYWEgplR

Links:

https://buff.ly/2uafeYE

Dr. John Cush RheumNow ( View Tweet)

Mar 16, 2019

The Weekly RheumNow Podcast is up! https://t.co/qA4wADpPN8 or listen to it on iTunes or SoundCloud https://t.co/mZ3y0yvwA3

Links:

Dr. John Cush RheumNow ( View Tweet)

Mar 15, 2019

FREE-Register to view into RheumNow Live next friday 3/22 >> https://t.co/lbrJ0Dp1Hb AFabulous Faculty - Calabrese, O'Shea, Weinblatt, Ruderman, Reveille, Langford, Seo, Kavanaugh, Conaghan, VanVollenhoven, Schett, Matteson, Wolfe, Pincus & more https://t.co/0NwHXWfjyO

Links:

Dr. John Cush RheumNow ( View Tweet)

Mar 15, 2019

2,933 adults >50 yrs went to the ER with a new vertebral fracture (2008-2014) but 98% did not have a DXA in 2yrs before and 1 yr after; and only 7% started OP Rx; In the ensuing 2 yrs, 38% developed another Fx https://t.co/JYYLFawV5z

Links:

https://buff.ly/2u7FHGr

Dr. John Cush RheumNow ( View Tweet)

Mar 15, 2019

QD44 - RA and Gout https://t.co/5a4rtwt1dw via @YouTube

Links:

https://youtu.be/vbK3eax-ghA

Dr. John Cush RheumNow ( View Tweet)

Mar 14, 2019

#1 Humira tops list of top selling drugs of 2018 at $19.9 Billion worldwide sales. Other Rheum drugs include #6 Rituxan $6.9 billion and #10 Stelara $5.2 billion https://t.co/mj5nTIQHL0

Links:

https://buff.ly/2T5kh6R

Dr. John Cush RheumNow ( View Tweet)

Mar 14, 2019

×